Construction
Compare Stocks
2 / 10Stock Comparison
JCI vs EMR
Revenue, margins, valuation, and 5-year total return — side by side.
Industrial - Machinery
JCI vs EMR — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Construction | Industrial - Machinery |
| Market Cap | $87.61B | $83.18B |
| Revenue (TTM) | $12.49B | $18.32B |
| Net Income (TTM) | $2.36B | $2.44B |
| Gross Margin | 71.5% | 39.4% |
| Operating Margin | 25.0% | 19.4% |
| Forward P/E | 30.2x | 22.8x |
| Total Debt | $11.19B | $13.76B |
| Cash & Equiv. | $379M | $1.54B |
JCI vs EMR — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Johnson Controls In… (JCI) | 100 | 455.7 | +355.7% |
| Emerson Electric Co. (EMR) | 100 | 242.4 | +142.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: JCI vs EMR
Each card shows where this stock fits in a portfolio — not just who wins on paper.
JCI carries the broadest edge in this set and is the clearest fit for long-term compounding and sleep-well-at-night.
- 354.6% 10Y total return vs EMR's 215.5%
- Lower volatility, beta 0.97, Low D/E 86.4%, current ratio 0.93x
- PEG 1.18 vs EMR's 5.04
EMR is the clearest fit if your priority is income & stability and growth exposure.
- Dividend streak 37 yrs, beta 1.52, yield 1.4%
- Rev growth 3.0%, EPS growth 17.8%, 3Y rev CAGR 9.3%
- 3.0% revenue growth vs JCI's 2.8%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 3.0% revenue growth vs JCI's 2.8% | |
| Value | Lower P/E (22.8x vs 30.2x) | |
| Quality / Margins | 18.9% margin vs EMR's 13.3% | |
| Stability / Safety | Beta 0.97 vs EMR's 1.52 | |
| Dividends | 1.4% yield, 37-year raise streak, vs JCI's 1.0% | |
| Momentum (1Y) | +62.9% vs EMR's +39.9% | |
| Efficiency (ROA) | 6.0% ROA vs EMR's 5.8%, ROIC 8.5% vs 8.2% |
JCI vs EMR — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
JCI vs EMR — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
JCI leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
EMR and JCI operate at a comparable scale, with $18.3B and $12.5B in trailing revenue. JCI is the more profitable business, keeping 18.9% of every revenue dollar as net income compared to EMR's 13.3%. On growth, EMR holds the edge at +2.9% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $12.5B | $18.3B |
| EBITDAEarnings before interest/tax | $3.6B | $4.7B |
| Net IncomeAfter-tax profit | $2.4B | $2.4B |
| Free Cash FlowCash after capex | $1.5B | $3.1B |
| Gross MarginGross profit ÷ Revenue | +71.5% | +39.4% |
| Operating MarginEBIT ÷ Revenue | +25.0% | +19.4% |
| Net MarginNet income ÷ Revenue | +18.9% | +13.3% |
| FCF MarginFCF ÷ Revenue | +11.7% | +17.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | -2.0% | +2.9% |
| EPS Growth (YoY)Latest quarter vs prior year | +45.8% | +28.2% |
Valuation Metrics
EMR leads this category, winning 5 of 7 comparable metrics.
Valuation Metrics
At 36.6x trailing earnings, EMR trades at a 33% valuation discount to JCI's 54.4x P/E. Adjusting for growth (PEG ratio), JCI offers better value at 2.12x vs EMR's 8.11x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | ||
|---|---|---|
| Market CapShares × price | $87.6B | $83.2B |
| Enterprise ValueMkt cap + debt − cash | $98.4B | $95.4B |
| Trailing P/EPrice ÷ TTM EPS | 54.43x | 36.61x |
| Forward P/EPrice ÷ next-FY EPS est. | 30.20x | 22.77x |
| PEG RatioP/E ÷ EPS growth rate | 2.12x | 8.11x |
| EV / EBITDAEnterprise value multiple | 26.65x | 18.89x |
| Price / SalesMarket cap ÷ Revenue | 3.71x | 4.62x |
| Price / BookPrice ÷ Book value/share | 7.23x | 4.13x |
| Price / FCFMarket cap ÷ FCF | 90.79x | 31.19x |
Profitability & Efficiency
JCI leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
JCI delivers a 16.6% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $12 for EMR. EMR carries lower financial leverage with a 0.68x debt-to-equity ratio, signaling a more conservative balance sheet compared to JCI's 0.86x. On the Piotroski fundamental quality scale (0–9), EMR scores 7/9 vs JCI's 6/9, reflecting strong financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | +16.6% | +12.1% |
| ROA (TTM)Return on assets | +6.0% | +5.8% |
| ROICReturn on invested capital | +8.5% | +8.2% |
| ROCEReturn on capital employed | +9.8% | +10.0% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 7 |
| Debt / EquityFinancial leverage | 0.86x | 0.68x |
| Net DebtTotal debt minus cash | $10.8B | $12.2B |
| Cash & Equiv.Liquid assets | $379M | $1.5B |
| Total DebtShort + long-term debt | $11.2B | $13.8B |
| Interest CoverageEBIT ÷ Interest expense | 57.59x | 6.61x |
Total Returns (Dividends Reinvested)
JCI leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in JCI five years ago would be worth $23,171 today (with dividends reinvested), compared to $16,900 for EMR. Over the past 12 months, JCI leads with a +62.9% total return vs EMR's +39.9%. The 3-year compound annual growth rate (CAGR) favors JCI at 32.8% vs EMR's 22.6% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | +17.4% | +9.3% |
| 1-Year ReturnPast 12 months | +62.9% | +39.9% |
| 3-Year ReturnCumulative with dividends | +134.1% | +84.1% |
| 5-Year ReturnCumulative with dividends | +131.7% | +69.0% |
| 10-Year ReturnCumulative with dividends | +354.6% | +215.5% |
| CAGR (3Y)Annualised 3-year return | +32.8% | +22.6% |
Risk & Volatility
JCI leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
JCI is the less volatile stock with a 0.97 beta — it tends to amplify market swings less than EMR's 1.52 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. JCI currently trades 97.2% from its 52-week high vs EMR's 89.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.97x | 1.52x |
| 52-Week HighHighest price in past year | $147.32 | $165.15 |
| 52-Week LowLowest price in past year | $87.77 | $106.53 |
| % of 52W HighCurrent price vs 52-week peak | +97.2% | +89.6% |
| RSI (14)Momentum oscillator 0–100 | 60.6 | 48.4 |
| Avg Volume (50D)Average daily shares traded | 3.3M | 2.8M |
Analyst Outlook
EMR leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Wall Street rates JCI as "Buy" and EMR as "Buy". Consensus price targets imply 9.5% upside for EMR (target: $162) vs -3.6% for JCI (target: $138). For income investors, EMR offers the higher dividend yield at 1.42% vs JCI's 1.04%.
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $138.00 | $161.92 |
| # AnalystsCovering analysts | 45 | 41 |
| Dividend YieldAnnual dividend ÷ price | +1.0% | +1.4% |
| Dividend StreakConsecutive years of raises | 5 | 37 |
| Dividend / ShareAnnual DPS | $1.49 | $2.10 |
| Buyback YieldShare repurchases ÷ mkt cap | +6.8% | +1.5% |
JCI leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). EMR leads in 2 (Valuation Metrics, Analyst Outlook).
JCI vs EMR: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is JCI or EMR a better buy right now?
For growth investors, Emerson Electric Co.
(EMR) is the stronger pick with 3. 0% revenue growth year-over-year, versus 2. 8% for Johnson Controls International plc (JCI). Emerson Electric Co. (EMR) offers the better valuation at 36. 6x trailing P/E (22. 8x forward), making it the more compelling value choice. Analysts rate Johnson Controls International plc (JCI) a "Buy" — based on 45 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — JCI or EMR?
On trailing P/E, Emerson Electric Co.
(EMR) is the cheapest at 36. 6x versus Johnson Controls International plc at 54. 4x. On forward P/E, Emerson Electric Co. is actually cheaper at 22. 8x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Johnson Controls International plc wins at 1. 18x versus Emerson Electric Co. 's 5. 04x — a reasonable growth-adjusted valuation.
03Which is the better long-term investment — JCI or EMR?
Over the past 5 years, Johnson Controls International plc (JCI) delivered a total return of +131.
7%, compared to +69. 0% for Emerson Electric Co. (EMR). Over 10 years, the gap is even starker: JCI returned +354. 6% versus EMR's +215. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — JCI or EMR?
By beta (market sensitivity over 5 years), Johnson Controls International plc (JCI) is the lower-risk stock at 0.
97β versus Emerson Electric Co. 's 1. 52β — meaning EMR is approximately 56% more volatile than JCI relative to the S&P 500. On balance sheet safety, Emerson Electric Co. (EMR) carries a lower debt/equity ratio of 68% versus 86% for Johnson Controls International plc — giving it more financial flexibility in a downturn.
05Which is growing faster — JCI or EMR?
By revenue growth (latest reported year), Emerson Electric Co.
(EMR) is pulling ahead at 3. 0% versus 2. 8% for Johnson Controls International plc (JCI). On earnings-per-share growth, the picture is similar: Emerson Electric Co. grew EPS 17. 8% year-over-year, compared to 4. 4% for Johnson Controls International plc. Over a 3-year CAGR, EMR leads at 9. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — JCI or EMR?
Johnson Controls International plc (JCI) is the more profitable company, earning 13.
9% net margin versus 12. 7% for Emerson Electric Co. — meaning it keeps 13. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: EMR leads at 19. 6% versus 12. 0% for JCI. At the gross margin level — before operating expenses — EMR leads at 52. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is JCI or EMR more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Johnson Controls International plc (JCI) is the more undervalued stock at a PEG of 1. 18x versus Emerson Electric Co. 's 5. 04x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Emerson Electric Co. (EMR) trades at 22. 8x forward P/E versus 30. 2x for Johnson Controls International plc — 7. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for EMR: 9. 5% to $161. 92.
08Which pays a better dividend — JCI or EMR?
All stocks in this comparison pay dividends.
Emerson Electric Co. (EMR) offers the highest yield at 1. 4%, versus 1. 0% for Johnson Controls International plc (JCI).
09Is JCI or EMR better for a retirement portfolio?
For long-horizon retirement investors, Johnson Controls International plc (JCI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
97), 1. 0% yield, +354. 6% 10Y return). Emerson Electric Co. (EMR) carries a higher beta of 1. 52 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JCI: +354. 6%, EMR: +215. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between JCI and EMR?
Both stocks operate in the Industrials sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.